Antibiotic Resurrection

Nemesis Bioscience has designed, and is developing, pioneering technologies that will resurrect anti-microbial therapies made ineffective by increasing microbial resistance.

These Nemesis symbiotics will impact one of the world’s most significant clinical problems by not only treating antibiotic resistant infections, but also by preventing them in susceptible patients.



Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s considerable experience into the company as it continues to rapidly grow the business around its portfolio of Nemesis Symbiotics© which inactivate antibiotic resistance in pathogenic bacteria MORE



The rapid spread of multi-drug resistant (MDR) bacteria means that we could be close to reaching a point where we may not be able to prevent or treat everyday infections or diseases. Many existing antimicrobials are becoming less effective. Bacteria, viruses and fungi are adapting naturally and becoming increasingly resistant to medicines used to treat the infections they cause. Inappropriate use of these valuable medicines has added to the problem. Coupled to this, the development pipeline for new antibiotics is at an all-time low. We must therefore conserve the antibiotics we have left by using them optimally. The process of developing new antimicrobials and new technologies to allow quicker diagnosis and facilitate targeted treatment must be accelerated.


Professor Dame Sally C. Davies

UK Chief Medical Officer


There are few public health issues of greater importance than antimicrobial resistance (AMR) in terms of impact on society

Antimicrobial resistance is one of our most serious health threats. Infections from resistant bacteria are now too common, and some pathogens have even become resistant to multiple types or classes of antibiotics (antimicrobials used to treat bacterial infections). The loss of effective antibiotics will undermine our ability to fight infectious diseases and manage the infectious complications common in vulnerable patients undergoing chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ transplantation, for which the ability to treat secondary infections is crucial.


Dr.Tom Frieden,

Director of the  U.S.Centers for Disease Control and Prevention



Nemesis Bioscience is developing, and will commercialise, therapeutic agents that will resurrect the antibiotic sensitivity of currently resistant microbial pathogens. These Nemesis symbiotics will both kill pathogenic microorganisms directly and/or make them susceptible to currently existing antibiotics.


This will make possible the ability to treat infections and to prophylactically prevent patients acquiring potentially life-threatening resistant pathogens in the first place. Nemesis symbiotics will be administered orally, topically and via dietary supplements.


The company has filed initial patent applications on its technologies and therapeutic approaches. More information is available by contacting us directly.


Frank Massam, PhD

Founder and Chief Executive Officer

Frank joined the company as CEO in July 2014. Before this he was Chief Operating Officer at Population Genetics Technologies with responsibility for the company’s commercial strategy and operations, including inward investment and out-licensing agreements with major life science organisations.

He was previously Senior Director of Strategic Planning and New Business Development at Agilent Technologies, President of Pharmagene, Inc. and Senior Director of Business Development at Incyte Genomics in California. At Incyte he led a team that out-licensed the company’s sequence and expression databases to senior executives at 28 of the world’s top 30 pharmaceutical companies.

Before this he was the President of AMS Neve, Inc., a Siemens company in the USA. He also founded and managed The Idbury Group, a life-science focused strategic marketing consultancy. Originally trained as a microbiologist in the UK’s Public Health Laboratory Service, he holds a PhD in Clinical Microbiology.

Professor Conrad Lichtenstein, PhD

Founder and Chief Scientific Officer

Conrad joined Nemesis Bioscience in 2014 after eight years as Chief Scientific Officer for Population Genetics Technologies where he developed methods to enable the rapid, low-cost, simultaneous analysis of candidate genes in multiple genomes and the identification of rare variants in mixed DNA samples from human, plant and microbial sources.

Following a PhD in Molecular Biology under Nobel Laureate Dr. Sydney Brenner at the MRC Laboratory of Molecular Biology in Cambridge, he held a post-doctoral position at the University of Washington, Seattle. After this, he took a faculty position at Imperial College London, followed by an appointment as Professor of Molecular Biology at Queen Mary, University of London.

His research has included gene targeting in plants by homologous recombination, RNAi engineering for virus resistance in transgenic plants and transposition by DNA elements spreading antibiotic resistance in bacteria. Conrad also holds a board position with Ilovani Ltd. in Cambridge.

Gi Mikawa, MD, PhD

Founder and Chief Medical Officer

Prior to joining Nemesis Bioscience, Gi was Principal Scientific Officer and a key early member of the team that created Population Genetics Technologies where he developed a novel DNA tagging technology that was subsequently licensed to New England Biolabs.

He also developed a variety of other technologies for DNA amplification via RNA and isolation of rare DNA variants from populations of DNA samples. Gi obtained his MD cum laude and PhD from the Jikei School of Medicine in Japan, and then joined the laboratory of Dr. Sydney Brenner in Cambridge, and at Lynx Therapeutics (later Illumina).

Subsequently he worked at the Molecular Sciences Institute and the Scripps Research Institute. Gi developed bacteriophage lambda peptide display and revealed the molecular mechanism of transmission of signals of  the E.coli chemotaxis receptor tar;  he performed studies using genetically engineered bacteria and bacteriophage of membrane proteins and drug/receptor interactions. He also serves on the board of Ilovani Ltd. in Cambridge.

Copyright © 2016 Nemesis Bioscience Ltd. All rights reserved


For more information on the company, its strategy and its science please contact us at:

Nemesis Bioscience Ltd - Cambridge site

Babraham Hall

Babraham Research Campus

Cambridge UK

CB22 3AT

Phone: +44 (0) 1223 804075


Nemesis Bioscience Ltd - Cardiff site

Unit 22, Cardiff Medicentre

Heath Park


CF14 4UJ